ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,442.00
2.14%
다우존스 지수
38,675.68
1.18%
Bitcoin
63,032.43
0.23%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. NeuroBo Pharmaceuticals Inc (NRBO)

  7. NeuroBo Pharmaceuticals Inc (NRBO) 뉴스

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NRBO
일자시간출처헤드라인심볼기업
2024/04/3021:01PR Newswire (US)NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/04/1721:05PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/04/0121:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/03/2821:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/03/1321:01PR Newswire (US)NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/03/0422:01PR Newswire (US)NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/03/0421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/2922:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/2922:01PR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/1422:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/1222:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/0122:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/02/0122:01PR Newswire (US)NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/01/1822:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/01/1822:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/01/0922:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/01/0922:30PR Newswire (US)NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2024/01/0222:01PR Newswire (US)NeuroBo to Participate in Industry and Investor Conferences in JanuaryNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/2823:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/2822:45PR Newswire (US)NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/1923:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/1922:43PR Newswire (US)NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/0723:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/12/0122:31PR Newswire (US)NeuroBo to Participate in Investor Conferences in DecemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/11/1406:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/11/1406:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/11/1406:05PR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/11/0622:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/11/0622:05PR Newswire (US)NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.NASDAQ:NRBONeuroBo Pharmaceuticals Inc
2023/10/3021:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:NRBO

최근 히스토리

NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
VZ
Verizon Communications
NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
NASDAQ
TSLA
Tesla
COIN
SOLUSD
Solana
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
CCOM
US500
US 500
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유